--- title: "Jacobson Pharma Corporation Limited (02633.HK)" type: "quote" locale: "en" url: "https://longbridge.com/en/quote/02633.HK.md" symbol: "02633.HK" name: "Jacobson Pharma Corporation Limited" industry: "Pharmaceuticals" --- # Jacobson Pharma Corporation Limited (02633.HK) | Item | Detail | |------|--------| | Industry | Pharmaceuticals | | Location | HK Market | | Website | [www.jacobsonpharma.com](https://www.jacobsonpharma.com) | ## Company Profile Jacobson Pharma Corporation Limited, through its subsidiaries, engages in the research, development, production, sale, and distribution of medicine and drugs in Hong Kong, Mainland China, Macau, Singapore, and internationally. It operates in two segments, Generic Drugs and Branded Healthcare. The co... ## Financial Score > *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.* > Updated: 2026-02-19T04:30:12.000Z **Overall: C (0.45)** **Industry**: Pharmaceuticals | Metric | Value | |--------|-------| | Industry Ranking | 29 / 48 | | Industry Median | C | | Industry Average | C | - **Style**: Value - Stocks where the company's main business is in a mature stage. - **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns. ### Score Analysis **Style Score**: #### Growth Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | -1.88% | | | Net Profit YoY | 19.49% | | #### Value Score: | Indicator | Value | Rating | |-----------|-------|--------| | P/B Ratio | 1.14 | | | Dividend Ratio | 12.40% | | **Size Score**: #### Market Cap Score: | Indicator | Value | Rating | |-----------|-------|--------| | Market Cap | 2.54B | | #### Revenue Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue | 1.53B | | **Multi Score**: C #### Profit Score: B | Indicator | Value | Rating | |-----------|-------|--------| | ROE | 12.97% | B | | Profit Margin | 19.73% | A | | Gross Margin | 44.07% | B | #### Growth Score: D | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | -1.88% | D | | Net Profit YoY | 19.49% | B | | Total Assets YoY | -2.19% | D | | Net Assets YoY | -8.03% | D | #### Cash Score: C | Indicator | Value | Rating | |-----------|-------|--------| | Cash Flow Margin | 506.79% | C | | OCF YoY | -1.88% | D | #### Operating Score: C | Indicator | Value | Rating | |-----------|-------|--------| | Turnover | 0.43 | C | #### Debt Score: B | Indicator | Value | Rating | |-----------|-------|--------| | Gearing Ratio | 35.97% | B | ```chart-data:radar { "title": "Longbridge Financial Score - Jacobson Pharma Corporation Limited", "chart_type": "radar", "dimensions": [ { "name": "Profit", "grade": "B", "indicators": [ { "name": "ROE", "value": "12.97%", "rating": "B" }, { "name": "Profit Margin", "value": "19.73%", "rating": "A" }, { "name": "Gross Margin", "value": "44.07%", "rating": "B" } ] }, { "name": "Growth", "grade": "D", "indicators": [ { "name": "Revenue YoY", "value": "-1.88%", "rating": "D" }, { "name": "Net Profit YoY", "value": "19.49%", "rating": "B" }, { "name": "Total Assets YoY", "value": "-2.19%", "rating": "D" }, { "name": "Net Assets YoY", "value": "-8.03%", "rating": "D" } ] }, { "name": "Cash", "grade": "C", "indicators": [ { "name": "Cash Flow Margin", "value": "506.79%", "rating": "C" }, { "name": "OCF YoY", "value": "-1.88%", "rating": "D" } ] }, { "name": "Operating", "grade": "C", "indicators": [ { "name": "Turnover", "value": "0.43", "rating": "C" } ] }, { "name": "Security", "grade": "B", "indicators": [ { "name": "Gearing Ratio", "value": "35.97%", "rating": "B" } ] } ] } ``` ### Peer Comparison | Rank | Name | Profit | Growth | Operation | Security | Cash | Rating | |------|------|--------|--------|-----------|----------|------|--------| | 01 | HENGRUI PHARMA (HK.1276) | A | B | C | A | B | B | | 02 | HANSOH PHARMA (HK.3692) | A | B | C | A | C | B | | 03 | SINO BIOPHARM (HK.1177) | B | B | C | B | B | B | | 04 | CMS (HK.867) | B | B | C | A | B | B | | 05 | SIMCERE PHARMA (HK.2096) | B | B | B | C | B | B | ## Valuation Analysis | Metric | Current | Industry Ranking | High | Median | Low | |--------|---------|-----------------|------|--------|-----| | PE (TTM) | 8.40 | 5/51 | 10.19 | 9.64 | 8.59 | | PB | 1.14 | 21/51 | 1.22 | 1.15 | 1.00 | | PS (TTM) | 1.66 | 19/51 | 1.88 | 1.70 | 1.56 | | Dividend Yield | 12.40% | 3/51 | 12.12% | 10.00% | 4.96% | ## Institutional View ### Analyst Rating Distribution > As of 2025-11-20T16:00:00.000Z Total Analysts: **1** | Rating | Count | Percentage | |--------|-------|-----------| | Buy | 1 | 100% | | Overweight | 0 | 0% | | Hold | 0 | 0% | | Underweight | 0 | 0% | | Sell | 0 | 0% | ### Target Price Forecast | Metric | Price | |--------|-------| | Current Price | 1.27 | | Highest Target | 2.53 | | Lowest Target | 2.53 | ## References - [Company Overview](https://longbridge.com/en/quote/02633.HK/overview.md) - Shareholders, executives, business segments - [Financials](https://longbridge.com/en/quote/02633.HK/norm.md) - Income statement, balance sheet, cash flow, distribution plan - [Topics & Discussions](https://longbridge.com/en/quote/02633.HK/topics.md) - Community topics and discussions --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.